SERENTIL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Feb 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 56m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERENTIL is an injectable small-molecule antipsychotic approved in 1970 for the treatment of psychotic disorders. The drug's exact mechanism of action and current indications are not fully documented in available data, though it represents a legacy antipsychotic class. As an older medication, it serves a defined but declining patient population.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal linked job opportunities, this brand operates with a lean team focused on maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SERENTIL offers limited career advancement potential due to its LOE status, minimal commercial activity, and zero linked job openings. Professionals joining this product would focus on lifecycle management, compliance, and risk mitigation rather than market growth or innovation.
Product Manager (Specialty Generics)Medical Science Liaison
Worked on SERENTIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.